Akeso Inc. has received approval from China's National Medical Products Administration (NMPA) for a phase Ib/II trial of ivonescimab (AK-112) combined with drebuxelimab (AK-119) for the treatment of advanced solid tumors.
PT Etana Biotechnologies Indonesia secured a series B financing of undisclosed value, led by Chinese investors that include Jack Ma’s Yunfeng Capital and Highlight Capital. The funds will be used to strengthen the company's pipeline and to expand its local manufacturing capacity.
Mablink Bioscience SAS raised €31 million (US$30.3 million) in a series A funding round and set its sights on a phase I trial of its lead next-generation antibody-drug conjugate (ADC), MBK-103, which is in development for a range of solid tumor indications. Sofinnova Partners and Mérieux Equity Partners co-led the round.
Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis.
Adlai Nortye Ltd. has described mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Hangzhou Apeloa Medicine Research Institute Co. Ltd. and Apeloa Pharmaceutical Co. Ltd. have disclosed fibroblast growth factor receptor 4 (FGFR-4) inhibitors reported to be useful for the treatment of cancer.
Investigators from the University of Copenhagen, Denmark have developed a cell line engineered to express bone morphogenetic protein 2 (BMP-2) and key extracellular matrix genes and critical factors that regulate and support human hematopoiesis. The findings were reported in the Oct. 12, 2022, issue of Science Translational Medicine. One of the clinical applications that the research team is interested in involves exploiting the MSOD-B hOss as a tumor model for bone colonization in the context of various cancers.
Odyssey Therapeutics Inc. closed a hefty $168 million series B round to progress multiple small-molecule and protein-based drug discovery and development programs in autoimmune disease and cancer.
RSS
